A big congratulations to our client, Xenikos, in closing this crucial strategic funding round to fuel Phase 3 clinical trials for their flagship T-Guard® product in the US and EU.
One of our specialties at Newman & Lickstein, LLP is helping life science & biotechnology professionals navigate through the pivotal moments of their corporate lifecycle to achieve their most critical business and legal goals.
Full press release: https://www.xenikos.com/xenikos-secures-e40-million-in-convertible-debt-financing-veloxis-pharmaceuticals-joins-as-strategic-investor/
